Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.
Also called NCT02689362
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 146 participants
- Sponsor
- Registry
-
NCT02689362
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT02689362. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-08 (actual); primary completion 2018-08-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)
- Acronym
- EVOLUTION
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Evogliptin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo Evogliptin
- Intervention (Drug)
- Placebo Sitagliptin
- Lead sponsor
- Eurofarma Laboratorios S.A.
Record details
- Record id
cardio:ct-nct02689362- Content hash
03adf8f2412ad33d7b87ffc7f262095e9bacae5d3a097e3dfbb0b13cb6dce5b0